



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PDE3A siRNA (h): sc-41592

BACKGROUND

Phosphodiesterases (PDE, also designated cyclic nucleotide phosphodiesterase) are important for the downregulation of the intracellular level of the second messenger cyclic adenosine monophosphate (cAMP) by hydrolyzing cAMP to 5'AMP. Phosphodiesterase type 3 isoforms, PDE3A and 3B, are expressed primarily in cardiovascular tissue and adipose tissue, respectively. PDE3A, is found in myocardium and platelets and PDE3B is found in lymphocytes. The PDE7A1 (HCP1) isozyme and the PDE7A2 proteins, alternate splice products of PDE7A, are highly expressed in skeletal muscle. PDE7B is most highly expressed in pancreas. The PDE family contains proteins that serve tissue-specific roles in regulation of lipolysis, glycogenolysis, myocardial contractility, and smooth muscle relaxation.

REFERENCES

- Bloom, T.J. and Beavo, J.A. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. *Proc. Natl. Acad. Sci. USA* 93: 14188-14192.
- Han, P., et al. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. *J. Biol. Chem.* 272: 16152-16157.
- Sheth, S.B., et al. 1997. Cyclic AMP phosphodiesterases in human lymphocytes. *Br. J. Haematol.* 99: 784-789.
- Fisher, D.A., et al. 1998. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. *Biochem. Biophys. Res. Commun.* 246: 570-577.

CHROMOSOMAL LOCATION

Genetic locus: PDE3A (human) mapping to 12p12.2.

PRODUCT

PDE3A siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PDE3A shRNA Plasmid (h): sc-41592-SH and PDE3A shRNA (h) Lentiviral Particles: sc-41592-V as alternate gene silencing products.

For independent verification of PDE3A (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-41592A, sc-41592B and sc-41592C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

PDE3A siRNA (h) is recommended for the inhibition of PDE3A expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

PDE3A (2D7): sc-293446 is recommended as a control antibody for monitoring of PDE3A gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PDE3A gene expression knockdown using RT-PCR Primer: PDE3A (h)-PR: sc-41592-PR (20 μ l, 575 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

- Penmatsa, H., et al. 2010. Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. *Mol. Biol. Cell* 21: 1097-1110.
- Rhee, D.K., et al. 2017. SFPQ, a multifunctional nuclear protein, regulates the transcription of PDE3A. *Biosci. Rep. pii: BSR20170975.*
- Xi, W., et al. 2018. Lack of microRNA-155 ameliorates renal fibrosis by targeting PDE3A/TGF- β 1/Smad signaling in mice with obstructive nephropathy. *Cell Biol. Int.* 42: 1523-1532.

RESEARCH USE

For research use only, not for use in diagnostic procedures.